

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

BIO RAD LABORATORIES INC
Form SC 13D
June 09, 2006

OMB APPROVAL

OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response.....11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. _____) *

Bio-Rad Laboratories, Inc.

(Name of Issuer)

Class A Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

090572207

(CUSIP Number)

Mark C. Wehrly
Farallon Capital Management, L.L.C.
One Maritime Plaza, Suite 1325
San Francisco, California 94111
(415) 421-2132

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 30, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 13d-1(f) or 240.13d-1(g), check the following box [].

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)
Page 1 of 51 Pages
Exhibit Index Found on Page 49

13D

=====
CUSIP No. 090572207
=====

NAMES OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Noonday Asset Management, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

2 ** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

		SOLE VOTING POWER
7		
NUMBER OF		-0-
		=====
		SHARED VOTING POWER
8		
SHARES		1,171,677
BENEFICIALLY		
OWNED BY		=====
		SOLE DISPOSITIVE POWER
9		
EACH		
		=====
		SHARED DISPOSITIVE POWER
10		
REPORTING		1,171,677
PERSON WITH		=====
		=====
11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		1,171,677
		=====
12		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []
		=====
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		5.5%
		=====
14		TYPE OF REPORTING PERSON (See Instructions)
		PN
		=====

Page 2 of 51 Pages

13D

=====

CUSIP No. 090572207

=====

		NAMES OF REPORTING PERSONS
1		I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
		Noonday G.P. (U.S.), L.L.C.
		=====
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
		(a) []
		(b) [X]**
2		

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

only of the securities reported by it on this cover page.

3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions)	
	OO	
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[]
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
		SOLE VOTING POWER
	NUMBER OF	7 -0-
	SHARES	
	BENEFICIALLY OWNED BY	8 SHARED VOTING POWER
	EACH	1,171,677
	REPORTING PERSON WITH	9 SOLE DISPOSITIVE POWER
		-0-
		10 SHARED DISPOSITIVE POWER
		1,171,677
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,171,677	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)	[]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	5.5%	
14	TYPE OF REPORTING PERSON (See Instructions)	
	OO	

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Noonday Capital, L.L.C.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
00

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

7 SOLE VOTING POWER
NUMBER OF -0-
SHARES
8 SHARED VOTING POWER
BENEFICIALLY OWNED BY 1,171,677
EACH
9 SOLE DISPOSITIVE POWER
REPORTING PERSON WITH -0-
10 SHARED DISPOSITIVE POWER
1,171,677

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.5%

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

 14 TYPE OF REPORTING PERSON (See Instructions)
 OO

13D

=====

 CUSIP No. 090572207

1 NAMES OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

David I. Cohen

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
 OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
 United States

	7	SOLE VOTING POWER
NUMBER OF		-0-
SHARES		-----
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		1,171,677
EACH		-----
		SOLE DISPOSITIVE POWER

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

9
 REPORTING PERSON WITH -----
 -0-
 SHARED DISPOSITIVE POWER
 10
 1,171,677

 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 1,171,677

 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 5.5%

 14 TYPE OF REPORTING PERSON (See Instructions)
 IN

Page 5 of 51 Pages

13D

=====
 CUSIP No. 090572207
 =====

 1 NAMES OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Saurabh K. Mittal

 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**

 ** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

 3 SEC USE ONLY

 4 SOURCE OF FUNDS (See Instructions)
 OO

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
India

7 SOLE VOTING POWER
NUMBER OF 7 -0-

8 SHARED VOTING POWER
SHARES BENEFICIALLY OWNED BY 8 1,171,677

9 SOLE DISPOSITIVE POWER
EACH 9
REPORTING PERSON WITH -0-

10 SHARED DISPOSITIVE POWER
10 1,171,677

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11 1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13 5.5%

14 TYPE OF REPORTING PERSON (See Instructions)
14 IN

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Noonday Capital Partners, L.L.C.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) []

(b) [X]**

2

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

3

SEC USE ONLY

4

SOURCE OF FUNDS (See Instructions)

WC, OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	7	SOLE VOTING POWER
NUMBER OF		-0-
SHARES		
BENEFICIALLY OWNED BY	8	SHARED VOTING POWER
EACH		19,400
REPORTING PERSON WITH	9	SOLE DISPOSITIVE POWER
		-0-
	10	SHARED DISPOSITIVE POWER
		19,400

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

19,400

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.1%

14

TYPE OF REPORTING PERSON (See Instructions)

OO

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Farallon Capital Partners, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**
 2

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

 3 SEC USE ONLY

SOURCE OF FUNDS (See Instructions)
 4
 WC, 00

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 5 TO ITEMS 2(d) OR 2(e) []

CITIZENSHIP OR PLACE OF ORGANIZATION
 6
 California

SOLE VOTING POWER
 7
 NUMBER OF -0-

SHARED VOTING POWER
 8
 SHARES 252,500
 BENEFICIALLY OWNED BY

SOLE DISPOSITIVE POWER
 9
 EACH -0-
 REPORTING PERSON WITH

SHARED DISPOSITIVE POWER
 10
 252,500

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 11
 252,500

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.2%

14 TYPE OF REPORTING PERSON (See Instructions)
PN

Page 8 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Farallon Capital Institutional Partners, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
WC

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
California

7 SOLE VOTING POWER

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

NUMBER OF	-0-	
SHARES		SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH	8	112,800
REPORTING PERSON WITH	9	SOLE DISPOSITIVE POWER
		-0-
	10	SHARED DISPOSITIVE POWER
		112,800

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
112,800

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.5%

14 TYPE OF REPORTING PERSON (See Instructions)
PN

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Farallon Capital Institutional Partners II, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

WC

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

California

		7	SOLE VOTING POWER
NUMBER OF			-0-
SHARES			
BENEFICIALLY	8		SHARED VOTING POWER
OWNED BY			14,800
EACH			
REPORTING	9		SOLE DISPOSITIVE POWER
PERSON WITH			-0-
	10		SHARED DISPOSITIVE POWER
			14,800

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

14,800

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.1%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

```

=====
NAMES OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Farallon Capital Institutional Partners III, L.P.
=====
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [ ]
(b) [ X ]**
2
** The reporting persons making this filing hold an
aggregate of 1,171,677 Shares, which is 5.5% of the
class of securities. The reporting person on this
cover page, however, is a beneficial owner only of
the securities reported by it on this cover page.
=====
3 SEC USE ONLY
=====
SOURCE OF FUNDS (See Instructions)
4
WC
=====
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
5 TO ITEMS 2(d) OR 2(e) [ ]
=====
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
=====
SOLE VOTING POWER
7
NUMBER OF -0-
SHARES BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH
8 SHARED VOTING POWER
8,600
9 SOLE DISPOSITIVE POWER
-0-
10 SHARED DISPOSITIVE POWER
8,600
=====
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,600
=====
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) [ ]
=====
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.0%
=====
14 TYPE OF REPORTING PERSON (See Instructions)
PN
=====

```

13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Tincum Partners, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**
 2

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

 3 SEC USE ONLY

SOURCE OF FUNDS (See Instructions)
 4
 WC, 00

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 5 TO ITEMS 2(d) OR 2(e) []

CITIZENSHIP OR PLACE OF ORGANIZATION
 6
 New York

	7	SOLE VOTING POWER
NUMBER OF		-0-
SHARES		-----
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		8,700
EACH	9	SOLE DISPOSITIVE POWER
REPORTING		-0-
PERSON WITH		-----
	10	SHARED DISPOSITIVE POWER
		8,700

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

=====

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,700

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.0%

14 TYPE OF REPORTING PERSON (See Instructions)
PN

=====

Page 12 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Farallon Capital Offshore Investors II, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
WC, OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

6

Cayman Islands

		SOLE VOTING POWER
7		
NUMBER OF		-0-
SHARES		SHARED VOTING POWER
BENEFICIALLY	8	
OWNED BY		228,300
EACH		SOLE DISPOSITIVE POWER
9		
REPORTING		-0-
PERSON WITH		
	10	SHARED DISPOSITIVE POWER
		228,300
11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		228,300
12		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		1.1%
14		TYPE OF REPORTING PERSON (See Instructions)
		PN

13D

=====
CUSIP No. 090572207
=====

		NAMES OF REPORTING PERSONS
1		I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
		Farallon Capital Management, L.L.C.
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
		(a) []
		(b) [X]**
2		

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions)	
	00	
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[]
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
		7
	NUMBER OF	SOLE VOTING POWER
		-0-
	SHARES	8
	BENEFICIALLY OWNED BY	SHARED VOTING POWER
	EACH	526,577
	REPORTING PERSON WITH	9
		SOLE DISPOSITIVE POWER
		-0-
		10
		SHARED DISPOSITIVE POWER
		526,577
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	526,577	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)	[]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	2.5%	
14	TYPE OF REPORTING PERSON (See Instructions)	
	IA, 00	

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Farallon Partners, L.L.C.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**

2
 ** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

 SOURCE OF FUNDS (See Instructions)
 4
 AF

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 5 TO ITEMS 2(d) OR 2(e) []

 CITIZENSHIP OR PLACE OF ORGANIZATION
 6
 Delaware

		SOLE VOTING POWER
NUMBER OF	7	-0-
SHARES		-----
BENEFICIALLY OWNED BY	8	SHARED VOTING POWER
EACH		645,100

		SOLE DISPOSITIVE POWER
REPORTING PERSON WITH	9	-0-

		SHARED DISPOSITIVE POWER
	10	645,100

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 11
 645,100

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.0%

14 TYPE OF REPORTING PERSON (See Instructions)
OO

Page 15 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Chun R. Ding

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
AF, OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

7 SOLE VOTING POWER
NUMBER OF -0-
SHARES SHARED VOTING POWER

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

BENEFICIALLY OWNED BY	8	1,171,677
EACH		SOLE DISPOSITIVE POWER
REPORTING PERSON WITH	9	-0-
		SHARED DISPOSITIVE POWER
	10	1,171,677

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.5%

14 TYPE OF REPORTING PERSON (See Instructions)
IN

Page 16 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

William F. Duhamel

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

4

AF, OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6

CITIZENSHIP OR PLACE OF ORGANIZATION United States

		SOLE VOTING POWER
7	NUMBER OF	-0-
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	SHARED VOTING POWER
8		1,171,677
		SOLE DISPOSITIVE POWER
9		-0-
		SHARED DISPOSITIVE POWER
10		1,171,677

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,171,677

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.5%

14

TYPE OF REPORTING PERSON (See Instructions) IN

CUSIP No. 090572207

1

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Richard B. Fried

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

```

=====
                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
                                (a) [   ]
                                (b) [ X ]**
2
                **      The reporting persons making this filing hold an
                        aggregate of 1,171,677 Shares, which is 5.5% of the
                        class of securities. The reporting person on this
                        cover page, however, may be deemed a beneficial owner
                        only of the securities reported by it on this cover
                        page.
=====
3      SEC USE ONLY
=====
4      SOURCE OF FUNDS (See Instructions)
      AF, 00
=====
5      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
      TO ITEMS 2(d) OR 2(e)                                [   ]
=====
6      CITIZENSHIP OR PLACE OF ORGANIZATION
      United States
=====
7      SOLE VOTING POWER
      NUMBER OF      7      -0-
      SHARES
      BENEFICIALLY      8      SHARED VOTING POWER
      OWNED BY      1,171,677
      EACH      9      SOLE DISPOSITIVE POWER
      REPORTING      -0-
      PERSON WITH      10      SHARED DISPOSITIVE POWER
                        1,171,677
=====
11     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      1,171,677
=====
12     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
      CERTAIN SHARES (See Instructions)                                [   ]
=====
13     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      5.5%
=====
14     TYPE OF REPORTING PERSON (See Instructions)
      IN
=====

```

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Page 18 of 51 Pages

13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Monica R. Landry

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**

2 ** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

 3 SEC USE ONLY

 SOURCE OF FUNDS (See Instructions)
 4 AF, OO

 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 5 TO ITEMS 2(d) OR 2(e) []

 CITIZENSHIP OR PLACE OF ORGANIZATION
 6 United States

 7 SOLE VOTING POWER
 NUMBER OF -0-

 8 SHARED VOTING POWER
 SHARES 1,171,677
 BENEFICIALLY OWNED BY

 9 SOLE DISPOSITIVE POWER
 EACH -0-

 10 SHARED DISPOSITIVE POWER
 REPORTING PERSON WITH 1,171,677

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.5%

14 TYPE OF REPORTING PERSON (See Instructions) IN

Page 19 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

William F. Mellin

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [] (b) [X]**

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions) AF, OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

United States

		SOLE VOTING POWER
7		
NUMBER OF		-0-
		SHARED VOTING POWER
8		
SHARES		1,171,677
BENEFICIALLY		
OWNED BY		SOLE DISPOSITIVE POWER
9		
EACH		-0-
		SHARED DISPOSITIVE POWER
10		
REPORTING		1,171,677
PERSON WITH		
		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11		
		1,171,677
		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
12		CERTAIN SHARES (See Instructions) []
		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13		
		5.5%
		TYPE OF REPORTING PERSON (See Instructions)
14		
		IN

Page 20 of 51 Pages

13D

CUSIP No. 090572207

		NAMES OF REPORTING PERSONS
1		I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
		Stephen L. Millham
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
		(a) []
		(b) [X]**
2		

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

only of the securities reported by it on this cover page.

3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions)	
	AF, OO	
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)	[]
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	United States	
		7
	NUMBER OF	SOLE VOTING POWER
		-0-
	SHARES	8
	BENEFICIALLY OWNED BY	SHARED VOTING POWER
	EACH	1,171,677
	REPORTING PERSON WITH	9
		SOLE DISPOSITIVE POWER
		-0-
		10
		SHARED DISPOSITIVE POWER
		1,171,677
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,171,677	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)	[]
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	5.5%	
14	TYPE OF REPORTING PERSON (See Instructions)	
	IN	

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 Jason E. Moment

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**
 2

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3 SEC USE ONLY

 SOURCE OF FUNDS (See Instructions)
 4 AF, 00

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
 United States

		7	SOLE VOTING POWER
NUMBER OF			-0-

		8	SHARED VOTING POWER
SHARES BENEFICIALLY OWNED BY			1,171,677

		9	SOLE DISPOSITIVE POWER
EACH REPORTING PERSON WITH			-0-

		10	SHARED DISPOSITIVE POWER
			1,171,677

 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

13

5.5%

14

TYPE OF REPORTING PERSON (See Instructions)
IN

Page 22 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1

=====
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Rajiv A. Patel
=====

2

=====
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) []
(b) [X]**
=====

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3

SEC USE ONLY

4

=====
SOURCE OF FUNDS (See Instructions)

AF, OO
=====

5

=====
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []
=====

6

=====
CITIZENSHIP OR PLACE OF ORGANIZATION

United States
=====

=====
7 SOLE VOTING POWER
NUMBER OF -0-

8 SHARED VOTING POWER
SHARES BENEFICIALLY OWNED BY 1,171,677
=====

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

EACH	SOLE DISPOSITIVE POWER
9	-0-
REPORTING PERSON WITH	-----
10	SHARED DISPOSITIVE POWER
	1,171,677
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,171,677
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	5.5%
14	TYPE OF REPORTING PERSON (See Instructions)
	IN

Page 23 of 51 Pages

13D

=====
CUSIP No. 090572207
=====

1	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
	Derek C. Schrier
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
	(a) []
	(b) [X]**
	** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions)
	AF, OO

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

7 SOLE VOTING POWER
NUMBER OF 7 -0-

8 SHARED VOTING POWER
SHARES BENEFICIALLY OWNED BY 8 1,171,677

9 SOLE DISPOSITIVE POWER
EACH 9
REPORTING PERSON WITH -0-

10 SHARED DISPOSITIVE POWER
10 1,171,677

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11 1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13 5.5%

14 TYPE OF REPORTING PERSON (See Instructions)
14 IN

=====
CUSIP No. 090572207
=====

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Thomas F. Steyer

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) []

(b) [X]**

2

** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

3

SEC USE ONLY

4

SOURCE OF FUNDS (See Instructions)

AF, OO

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []

6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

		7	SOLE VOTING POWER
NUMBER OF			-0-
SHARES			
BENEFICIALLY	8		SHARED VOTING POWER
OWNED BY			1,171,677
EACH			
REPORTING	9		SOLE DISPOSITIVE POWER
PERSON WITH			-0-
	10		SHARED DISPOSITIVE POWER
			1,171,677

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,171,677

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.5%

14

TYPE OF REPORTING PERSON (See Instructions)

IN

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Page 25 of 51 Pages

13D

=====
 CUSIP No. 090572207
 =====

 NAMES OF REPORTING PERSONS
 1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Mark C. Wehrly

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a) []
 (b) [X]**

2 ** The reporting persons making this filing hold an aggregate of 1,171,677 Shares, which is 5.5% of the class of securities. The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

 3 SEC USE ONLY

 SOURCE OF FUNDS (See Instructions)
 4 AF, OO

 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
 5 TO ITEMS 2(d) OR 2(e) []

 CITIZENSHIP OR PLACE OF ORGANIZATION
 6 United States

 7 SOLE VOTING POWER
 NUMBER OF -0-

 8 SHARED VOTING POWER
 SHARES 1,171,677
 BENEFICIALLY OWNED BY

 9 SOLE DISPOSITIVE POWER
 EACH -0-

 10 SHARED DISPOSITIVE POWER
 REPORTING PERSON WITH 1,171,677

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

1,171,677

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.5%

14 TYPE OF REPORTING PERSON (See Instructions) IN

Page 26 of 51 Pages

Item 1. Security And Issuer

This statement relates to shares of Class A Common Stock, par value \$0.0001 per share (the "Shares"), of Bio-Rad Laboratories, Inc. (the "Company"). The Company's principal offices are located at 1000 Alfred Nobel Drive, Hercules, California 94547.

Item 2. Identity And Background

(a) This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons."

The Noonday Sub-adviser Entities

- (i) Noonday G.P. (U.S.), L.L.C., a Delaware limited liability company which is a sub-investment adviser(1) to each of the Funds and the Managed Accounts (the "First Noonday Sub-adviser"), with respect to all of the Shares held by the Funds and the Managed Accounts;
(ii) Noonday Asset Management, L.P., a Delaware limited partnership which is a sub-investment adviser(1) to each of the Funds and the Managed Accounts (the "Second Noonday Sub-adviser"), with respect to all of the Shares held by the Funds and the Managed Accounts; and
(iii) Noonday Capital, L.L.C., a Delaware limited liability company which is the general partner of the Second Noonday Sub-adviser (the "Noonday General Partner"), with respect to all of the Shares held by Funds and the Managed Accounts.

The First Noonday Sub-adviser, the Second Noonday Sub-adviser and the

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Noonday General Partner are together referred to herein as the "Noonday Sub-adviser Entities."

The Noonday Managing Members

- (iv) David I. Cohen ("Cohen") and Saurabh K. Mittal ("Mittal"), the managing members of both the First Noonday Sub-adviser and the Noonday General Partner, with respect to all of the Shares held by the Funds and the Managed Accounts.

Cohen and Mittal are referred to herein as the "Noonday Individual Reporting Persons."

(1) The First Noonday Sub-adviser and the Second Noonday Sub-adviser entered into certain subadvisory arrangements with the Management Company and the Farallon General Partner effective as of January 1, 2005, pursuant to which the First Noonday Sub-adviser and the Second Noonday Sub-adviser were granted investment discretion over all of the assets of the Noonday Fund and certain of the assets of the Farallon Funds and the Managed Accounts.

Page 27 of 51 Pages

The Noonday Fund

- (v) Noonday Capital Partners, L.L.C., a Delaware limited liability company (the "Noonday Fund"), with respect to the Shares held by it.

The Farallon Funds

- (vi) Farallon Capital Partners, L.P., a California limited partnership ("FCP"), with respect to the Shares held by it;
- (vii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"), with respect to the Shares held by it;
- (viii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"), with respect to the Shares held by it;
- (ix) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"), with respect to the Shares held by it;
- (x) Tinicum Partners, L.P., a New York limited partnership ("Tinicum"), with respect to the Shares held by it; and
- (xi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"), with respect to the Shares held by it.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

FCP, FCIP, FCIP II, FCIP III, Tincum and FCOI II are together referred to herein as the "Farallon Funds." The Noonday Fund and the Farallon Funds are together referred to herein as the "Funds."

The Farallon General Partner

- (xii) Farallon Partners, L.L.C., a Delaware limited liability company which is the general partner of each of the Farallon Funds and the managing member of the Noonday Fund (the "Farallon General Partner"), with respect to the Shares held by each of the Funds.

The Farallon Managing Members

- (xiii) The following persons who are managing members of both the Farallon General Partner and the Management Company, with respect to the Shares held by the Funds and the Managed Accounts: Chun R. Ding ("Ding"), William F. Duhamel ("Duhamel"), Richard B. Fried ("Fried"), Monica R. Landry ("Landry"), William F. Mellin ("Mellin"), Stephen L. Millham ("Millham"), Jason E. Moment ("Moment"), Rajiv A. Patel ("Patel"), Derek C. Schrier ("Schrier"), Thomas F. Steyer ("Steyer") and Mark C. Wehrly ("Wehrly").

Page 28 of 51 Pages

Ding, Duhamel, Fried, Landry, Mellin, Millham, Moment, Patel, Schrier, Steyer and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons." The Noonday Individual Reporting Persons and the Farallon Individual Reporting Persons are together referred to herein as the "Individual Reporting Persons."

(b) The address of the principal business and principal office of (i) the Funds, the Management Company and the Farallon General Partner is One Maritime Plaza, Suite 1325, San Francisco, California 94111, (ii) the Noonday Sub-adviser Entities is 227 West Trade Street, Suite 2140, Charlotte, North Carolina 28202 and (iii) each of the Individual Reporting Persons is set forth in Annex 1 hereto.

(c) The principal business of each of the Funds is that of a private investment fund engaging in the purchase and sale of investments for its own account. The principal business of the First Noonday Sub-adviser and the Second Noonday Sub-adviser is to act as a sub-investment adviser to the Funds and the Managed Accounts. The principal business of the Noonday General Partner is to act as the general partner of the Second Noonday Sub-adviser. The principal business of the Management Company is that of a registered investment adviser. The principal business of the Farallon General Partner is to act as the general partner of the Farallon Funds and the managing member of the Noonday Fund. The principal business of each of the Individual Reporting Persons is set forth in Annex 1 hereto.

(d) None of the Funds, the Noonday Sub-adviser Entities, the Management

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Company, the Farallon General Partner or the Individual Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Funds, the Noonday Sub-adviser Entities, the Management Company, the Farallon General Partner or the Individual Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The citizenship of each of the Funds, the Noonday Sub-adviser Entities, the Management Company and the Farallon General Partner is set forth above. Each of the Individual Reporting Persons other than Mittal is a citizen of the United States. Mittal is a citizen of India.

The other information required by Item 2 relating to the identity and background of the Reporting Persons is set forth in Annex 1 hereto.

Item 3. Source And Amount Of Funds And Other Consideration

The net investment cost (including commissions) for the Shares held by each of the Funds and the Managed Accounts is set forth below:

Page 29 of 51 Pages

Entity -----	Shares Held -----	Approximate Net Investment Cost -----
Noonday Fund	19,400	\$1,301,082.00
FCP	252,500	\$16,906,711.00
FCIP	112,800	\$7,572,120.00
FCIP II	14,800	\$993,733.00
FCIP III	8,600	\$579,276.00
Tinicum	8,700	\$583,478.00
FCOI II	228,300	\$15,281,281.00
Managed Accounts	526,577	\$35,249,714.00

The consideration for such acquisitions was obtained as follows: (i) with respect to the Noonday Fund, FCP, Tinicum and FCOI II, from working capital and/or from borrowings pursuant to margin accounts maintained in the ordinary course of business by the Noonday Fund, FCP, Tinicum and FCOI II at Goldman, Sachs & Co.; (ii) with respect to FCIP, FCIP II and FCIP III, from working capital; and (iii) with respect to the Managed Accounts, from the working capital of the Managed Accounts and/or from borrowings pursuant to margin accounts maintained in the ordinary course of business by some of the Managed Accounts at Goldman, Sachs & Co. The Noonday Fund, FCP, Tinicum, FCOI II and some of the Managed Accounts hold certain securities in their respective margin accounts at Goldman, Sachs & Co., and the accounts may from time to time have debit balances. It is not possible to determine the amount of borrowings, if any, used to acquire the Shares.

Item 4. Purpose Of The Transaction

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

The purpose of the acquisition of the Shares is for investment and the acquisitions of the Shares by each of the Funds and the Managed Account were made in the ordinary course of business and were not made for the purpose of acquiring control of the Company.

Although no Reporting Person has any specific plan or proposal to acquire or dispose of Shares, consistent with its investment purpose, each Reporting Person at any time and from time to time may acquire additional Shares or dispose of any or all of its Shares depending upon an ongoing evaluation of the investment in the Shares, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. No Reporting Person has made a determination regarding a maximum or minimum number of Shares which it may hold at any point in time.

Also, consistent with their investment intent, the Reporting Persons intend to engage in communications with one or more officers of the Company and/or one or more members of the board of directors of the Company and may engage in communication with one or more shareholders of the Company regarding the Company, including but not limited to its operations, capital structure, potential strategies to enhance shareholder value, composition of the board of directors and/or any current or future initiatives that may be proposed or adopted by the Company's management or board of directors. During the course of such communications, the Reporting Persons may advocate or oppose one or more courses of action. The Reporting Persons have previously suggested to the chairman of the board that the Company consider changes to the

Page 30 of 51 Pages

composition of the board of directors. The Reporting Persons may pursue further conversations with one or more members of the board of directors or other persons regarding these and/or other similar suggestions.

Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

Item 5. Interest In Securities Of The Issuer

(a) The Funds

(a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for each Fund is incorporated herein by reference for each such Fund. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 21,426,035 Shares outstanding as of April 30, 2006 as reported by the Company in its Quarterly Report on Form 10-Q for the period ended March 31, 2006 filed

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

with the Securities and Exchange Commission on May 9, 2006.

- (c) The trade dates, number of Shares purchased or sold and the price per Share (including commissions) for all purchases and sales of the Shares by the Funds in the past 60 days are set forth on Schedules A-G hereto and are incorporated herein by reference. All of such transactions were open-market transactions.
 - (d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Funds as reported herein. The Noonday General Partner is the general partner of the Second Noonday Sub-adviser. The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of the Farallon General Partner.
 - (e) Not applicable.
- (b) The Noonday Sub-adviser Entities

- (a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for each Noonday Sub-adviser Entity is incorporated herein by reference for each such Noonday Sub-adviser Entity.

Page 31 of 51 Pages

- (c) None.
- (d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser, and the Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Funds as reported herein. Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Management Company has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Managed Accounts as reported herein. The Noonday General Partner is the general partner of the Second Noonday Sub-adviser. The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of both the Farallon General Partner and the Management Company.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

(e) Not applicable.

(c) The Noonday Individual Reporting Persons

(a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for each Noonday Individual Reporting Person is incorporated herein by reference for each such Noonday Individual Reporting Person.

(c) None.

(d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Funds. Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Management Company has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Managed Accounts. The Noonday General Partner is the general partner of the Second Noonday Sub-adviser. The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of both the Farallon General Partner and the Management Company.

(e) Not applicable.

(d) The Management Company

(a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for the Management Company is incorporated herein by reference.

Page 32 of 51 Pages

(c) The trade dates, number of Shares purchased or sold and the price per Share (including commissions) for all purchases and sales of the Shares by the Management Company on behalf of the Managed Accounts in the past 60 days are set forth on Schedule H hereto and are incorporated herein by reference. All of such transactions were open-market transactions.

(d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Management Company has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Managed Accounts as reported herein. The Noonday General Partner is the general partner of the Second Noonday Sub-adviser.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of the Management Company.

(e) Not applicable.

(e) The Farallon General Partner

(a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for the Farallon General Partner is incorporated herein by reference.

(c) None.

(d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Funds as reported herein. The Noonday General Partner is the general partner of the Second Noonday Sub-adviser. The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of the Farallon General Partner.

(e) Not applicable.

(f) The Farallon Individual Reporting Persons

(a), (b) The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Individual Reporting Person is incorporated herein by reference for each such Farallon Individual Reporting Person.

(c) None.

Page 33 of 51 Pages

(d) Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Funds as reported herein. Each of the First Noonday Sub-adviser, the Second Noonday Sub-adviser and the Management Company has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, all of the Shares held by the Managed Accounts as reported herein. The Noonday General Partner is the general partner of the

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

Second Noonday Sub-adviser. The Noonday Individual Reporting Persons are managing members of both the First Noonday Sub-adviser and the Noonday General Partner. The Farallon Individual Reporting Persons are managing members of both the Farallon General Partner and the Management Company.

(e) Not applicable.

The Shares reported hereby for the Funds are owned directly by the Funds and those reported by the Management Company on behalf of the Managed Accounts are owned directly by the Managed Accounts. The First Noonday Sub-adviser and the Second Noonday Sub-adviser, as sub-investment advisers to the Funds and the Managed Accounts, may be deemed to be the beneficial owners of all such Shares owned by the Funds and the Managed Accounts. The Noonday General Partner, as general partner to the Second Noonday Sub-adviser, may be deemed to be the beneficial owner of all such Shares owned by the Funds and the Managed Accounts. The Noonday Individual Reporting Persons, as managing members of both the First Noonday Sub-adviser and the Noonday General Partner, may each be deemed to be the beneficial owner of all such Shares owned by the Funds and the Managed Accounts. The Management Company, as investment adviser to the Managed Accounts, may be deemed to be the beneficial owner of all such Shares owned by the Managed Accounts. The Farallon General Partner, as general partner to the Farallon Funds and managing member of the Noonday Fund, may be deemed to be the beneficial owner of all such Shares owned by the Funds. The Farallon Individual Reporting Persons, as managing members of both the Management Company and the Farallon General Partner with the power to exercise investment discretion, may each be deemed to be the beneficial owner of all such Shares owned by the Funds and the Managed Accounts. Each of the Noonday Sub-adviser Entities, the Management Company, the Farallon General Partner and the Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.

Item 6. Contracts, Arrangements, Understandings Or

Relationships With Respect To Securities Of The Issuer

Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Company, including but not limited to the transfer or voting of any securities of the Company, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

Page 34 of 51 Pages

Item 7. Materials To Be Filed As Exhibits

There is filed herewith as Exhibit 1 a written agreement relating to the filing of joint acquisition statements as required by Section 240.13d-1(k) under the Securities Exchange Act of 1934, as amended.

Page 35 of 51 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: June 9, 2006

/s/ Monica R. Landry

NOONDAY G.P. (U.S.), L.L.C.
By Monica R. Landry, Attorney-in-fact

/s/ Monica R. Landry

NOONDAY CAPITAL, L.L.C.,
On its own behalf
and as the General Partner of
NOONDAY ASSET MANAGEMENT, L.P.
By Monica R. Landry, Attorney-in-fact

/s/ Monica R. Landry

FARALLON PARTNERS, L.L.C.,
On its own behalf,
as the General Partner of
FARALLON CAPITAL PARTNERS, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
TINICUM PARTNERS, L.P. and
FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.
and as the Managing Member of
NOONDAY CAPITAL PARTNERS, L.L.C.
By Monica R. Landry, Managing Member

/s/ Monica R. Landry

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

FARALLON CAPITAL MANAGEMENT, L.L.C.
By Monica R. Landry, Managing Member

/s/ Monica R. Landry

Monica R. Landry, individually and as attorney-in-fact for each of David I. Cohen, Chun R. Ding, William F. Duhamel, Richard B. Fried, William F. Mellin, Stephen L. Millham, Saurabh K. Mittal, Jason E. Moment, Rajiv A. Patel, Derek C. Schrier, Thomas F. Steyer and Mark C. Wehrly

Page 36 of 51 Pages

The Powers of Attorney executed by Duhamel, Fried, Mellin, Millham, Steyer and Wehrly authorizing Landry to sign and file this Schedule 13D on each person's behalf, which were filed with Amendment No. 2 to the Schedule 13D filed with the Securities and Exchange Commission on July 16, 2003, by such Reporting Persons with respect to the Class A Common Stock of New World Restaurant Group, Inc., are hereby incorporated by reference. The Powers of Attorney executed by Ding and Schrier authorizing Landry to sign and file this Schedule 13D on each person's behalf, which were filed with Amendment No. 1 to the Schedule 13D filed with the Securities and Exchange Commission on July 2, 2003, by such Reporting Persons with respect to the Class A Common Stock of Salix Pharmaceuticals, Ltd., are hereby incorporated by reference. The Power of Attorney executed by Patel authorizing Landry to sign and file this Schedule 13D on his behalf, which was filed with Amendment No. 4 to the Schedule 13G filed with the Securities and Exchange Commission on January 8, 2004, by such Reporting Person with respect to the Class A Common Stock of Catalytica Energy Systems, Inc., is hereby incorporated by reference. The Powers of Attorney executed by Noonday G.P. (U.S.), L.L.C., Noonday Asset Management, L.P., Noonday Capital, L.L.C. and Cohen authorizing Landry to sign and file this Schedule 13D on its or his behalf, which were filed with Amendment No. 5 to the Schedule 13G filed with the Securities and Exchange Commission on January 10, 2005, by such Reporting Persons with respect to the Class A Common Stock of Catalytica Energy Systems, Inc., are hereby incorporated by reference. The Power of Attorney executed by Mittal authorizing Landry to sign and file this Schedule 13D on his behalf, which was filed with Amendment No. 6 to the Schedule 13G filed with the Securities and Exchange Commission on October 5, 2005, by such Reporting Person with respect to the Class A Common Stock of Catalytica Energy Systems, Inc., is hereby incorporated by reference. The Power of Attorney executed by Moment authorizing Landry to sign and file this Schedule 13D on his behalf, which was filed with the Schedule 13D filed with the Securities and Exchange Commission on January 9, 2006, by such Reporting Person with respect to the Class A Common Stock of Vintage Petroleum, Inc., is hereby incorporated by reference.

Page 37 of 51 Pages

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

ANNEX 1

Set forth below with respect to the Noonday Sub-adviser Entities, the Management Company and the Farallon General Partner is the following information: (a) name; (b) address; (c) principal business; (d) state of organization; and (e) controlling persons. Set forth below with respect to each Individual Reporting Person is the following information: (a) name; (b) business address; (c) principal occupation; and (d) citizenship.

1. The First Noonday Sub-adviser

- (a) Noonday G.P. (U.S.), L.L.C.
- (b) c/o Noonday Asset Management, L.P.
227 West Trade Street, Suite 2140
Charlotte, North Carolina 28202
- (c) Serves as sub-investment adviser to investment funds
- (d) Delaware limited liability company
- (e) Managing Members: David I. Cohen and Saurabh K. Mittal

2. The Second Noonday Sub-adviser

- (a) Noonday Asset Management, L.P.
- (b) 227 West Trade Street, Suite 2140
Charlotte, North Carolina 28202
- (c) Serves as sub-investment adviser to investment funds
- (d) Delaware limited partnership
- (e) David I. Cohen and Saurabh K. Mittal, the managing members of
its general partner

3. The Noonday General Partner

- (a) Noonday Capital, L.L.C.
- (b) c/o Noonday Asset Management, L.P.
227 West Trade Street, Suite 2140
Charlotte, North Carolina 28202
- (c) Serves as general partner of the Second Noonday Sub-adviser
- (d) Delaware limited liability company
- (e) Managing Members: David I. Cohen and Saurabh K. Mittal

4. The Noonday Individual Reporting Persons

Cohen is a citizen of the United States. Mittal is a citizen of India. The business address of each of the Noonday Individual Reporting Persons is c/o Noonday Asset Management, L.P., 227 West Trade Street, Suite 2140, Charlotte, North Carolina 28202. The principal occupation of each of the Noonday Individual Reporting Persons is serving as the managing member of both the First Noonday Sub-adviser and the Noonday General Partner. The Noonday Individual Reporting Persons do not have any additional information to disclose

Page 38 of 51 Pages

with respect to Items 2-6 of the Schedule 13D that is not already

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

disclosed in the Schedule 13D.

5. The Management Company

- (a) Farallon Capital Management, L.L.C.
- (b) One Maritime Plaza, Suite 1325
San Francisco, California 94111
- (c) Serves as investment adviser to various managed accounts
- (d) Delaware limited liability company
- (e) Managing Members: Thomas F. Steyer, Senior Managing Member;
Chun R. Ding, William F. Duhamel, Alice F. Evarts, Richard B.
Fried, Monica R. Landry, William F. Mellin, Stephen L.
Millham, Jason E. Moment, Rajiv A. Patel, Derek C. Schrier,
Gregory S. Swart and Mark C. Wehrly, Managing Members.

6. The Farallon General Partner

- (a) Farallon Partners, L.L.C.
- (b) c/o Farallon Capital Management, L.L.C.
One Maritime Plaza, Suite 1325
San Francisco, California 94111
- (c) Serves as general partner to investment partnerships
- (d) Delaware limited liability company
- (e) Managing Members: Thomas F. Steyer, Senior Managing Member;
Chun R. Ding, William F. Duhamel, Alice F. Evarts, Richard B.
Fried, Monica R. Landry, William F. Mellin, Stephen L.
Millham, Jason E. Moment, Rajiv A. Patel, Derek C. Schrier,
Gregory S. Swart and Mark C. Wehrly, Managing Members.

7. Managing Members of the Management Company and the Farallon General

Partner

Each of the managing members of the Management Company and the Farallon General Partner other than Swart is a citizen of the United States. Swart is a citizen of New Zealand. The business address of each of the managing members of the Management Company and the Farallon General Partner is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 1325, San Francisco, California 94111. The principal occupation of Thomas F. Steyer is serving as senior managing member of both the Management Company and the Farallon General Partner. The principal occupation of each other managing member of the Management Company and the Farallon General Partner is serving as a managing member of both the Management Company and the Farallon General Partner. None of the managing members of the Management Company and the Farallon General Partner has any additional information to disclose with respect to Items 2-6 of the Schedule 13D that is not already disclosed in the Schedule 13D.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

 NOONDAY CAPITAL PARTNERS, L.L.C.

TRADE DATE -----	NO. OF SHARES PURCHASED -----	PRICE PER SHARE (\$) -----
4/10/2006	700	\$63.19
4/11/2006	100	\$62.11
4/12/2006	100	\$62.30
4/17/2006	100	\$63.22
4/18/2006	100	\$64.44
4/20/2006	500	\$66.25
4/21/2006	200	\$66.25
4/24/2006	700	\$66.26
4/25/2006	4,900	\$66.27
5/3/2006	500	\$65.01
5/4/2006	800	\$65.45
5/9/2006	300	\$71.00
5/10/2006	300	\$71.25
5/11/2006	700	\$71.24
5/12/2006	1,300	\$71.24
5/15/2006	700	\$70.82
5/17/2006	500	\$70.21
5/18/2006	600	\$70.47
5/19/2006	300	\$69.60
5/22/2006	400	\$69.43
5/23/2006	500	\$69.12
5/24/2006	100	\$67.10
5/24/2006	600	\$66.58
5/25/2006	800	\$67.90
5/26/2006	300	\$68.26
5/30/2006	400	\$66.86
5/31/2006	400	\$66.51
6/2/2006	500	\$66.91
6/6/2006	400	\$65.10
6/8/2006	100	\$64.86

Page 40 of 51 Pages

SCHEDULE B

FARALLON CAPITAL PARTNERS, L.P.

TRADE DATE -----	NO. OF SHARES PURCHASED -----	PRICE PER SHARE (\$) -----
4/10/2006	12,900	\$63.19

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

4/11/2006	1,800	\$62.11
4/12/2006	7	\$62.30
4/12/2006	893	\$62.30
4/13/2006	200	\$62.33
4/17/2006	2,000	\$63.22
4/18/2006	1,500	\$64.44
4/19/2006	300	\$65.09
4/20/2006	8,800	\$66.25
4/21/2006	3,700	\$66.25
4/24/2006	11,200	\$66.26
4/25/2006	59,900	\$66.27
5/3/2006	6,900	\$65.01
5/4/2006	8,500	\$65.45
5/9/2006	3,300	\$71.00
5/10/2006	2,900	\$71.25
5/11/2006	7,500	\$71.24
5/12/2006	15,300	\$71.24
5/15/2006	7,900	\$70.82
5/17/2006	6,700	\$70.21
5/18/2006	6,800	\$70.47
5/19/2006	3,300	\$69.60
5/22/2006	4,300	\$69.43
5/23/2006	7,900	\$69.12
5/24/2006	1,600	\$67.10
5/24/2006	8,200	\$66.58
5/25/2006	12,600	\$67.90
5/26/2006	5,300	\$68.26
5/30/2006	5,600	\$66.86
5/31/2006	5,300	\$66.51
6/2/2006	4,600	\$66.91
6/6/2006	3,900	\$65.10
6/8/2006	800	\$64.86

Page 41 of 51 Pages

SCHEDULE C

 FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.

TRADE DATE	NO. OF SHARES PURCHASED	PRICE PER SHARE (\$)
-----	-----	-----
4/10/2006	4,100	\$63.19
4/11/2006	600	\$62.11
4/12/2006	1	\$62.30
4/12/2006	299	\$62.30
4/13/2006	100	\$62.33
4/17/2006	900	\$63.22
4/18/2006	400	\$64.44

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

4/19/2006	100	\$65.09
4/20/2006	3,000	\$66.25
4/21/2006	1,500	\$66.25
4/24/2006	4,300	\$66.26
4/25/2006	21,100	\$66.27
5/3/2006	2,000	\$65.01
5/4/2006	3,200	\$65.45
5/9/2006	1,400	\$71.00
5/10/2006	1,300	\$71.25
5/11/2006	3,700	\$71.24
5/12/2006	7,700	\$71.24
5/15/2006	3,800	\$70.82
5/17/2006	3,300	\$70.21
5/18/2006	3,300	\$70.47
5/19/2006	1,700	\$69.60
5/22/2006	2,100	\$69.43
5/23/2006	3,800	\$69.12
5/24/2006	4,000	\$66.58
5/24/2006	800	\$67.10
5/25/2006	6,200	\$67.90
5/26/2006	3,900	\$68.26
5/30/2006	3,900	\$66.86
5/31/2006	3,800	\$66.51
6/2/2006	3,700	\$66.91
6/6/2006	2,900	\$65.10
6/8/2006	600	\$64.86

Page 42 of 51 Pages

SCHEDULE D

 FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.

TRADE DATE	NO. OF SHARES PURCHASED	PRICE PER SHARE (\$)
-----	-----	-----
4/10/2006	700	\$63.19
4/11/2006	100	\$62.11
4/17/2006	100	\$63.22
4/18/2006	100	\$64.44
4/20/2006	400	\$66.25
4/21/2006	200	\$66.25
4/24/2006	600	\$66.26
4/25/2006	3,500	\$66.27
5/3/2006	400	\$65.01
5/4/2006	400	\$65.45
5/9/2006	200	\$71.00
5/10/2006	200	\$71.25
5/11/2006	500	\$71.24
5/12/2006	1,000	\$71.24
5/15/2006	500	\$70.82
5/17/2006	500	\$70.21

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

5/18/2006	400	\$70.47
5/19/2006	200	\$69.60
5/22/2006	300	\$69.43
5/23/2006	500	\$69.12
5/24/2006	600	\$66.58
5/24/2006	100	\$67.10
5/25/2006	800	\$67.90
5/26/2006	300	\$68.26
5/30/2006	300	\$66.86
5/31/2006	300	\$66.51
6/2/2006	300	\$66.91
6/6/2006	200	\$65.10

Page 43 of 51 Pages

SCHEDULE E

 FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.

TRADE DATE	NO. OF SHARES PURCHASED	PRICE PER SHARE (\$)
-----	-----	-----
4/10/2006	500	\$63.19
4/11/2006	100	\$62.11
4/17/2006	100	\$63.22
4/20/2006	300	\$66.25
4/21/2006	100	\$66.25
4/24/2006	500	\$66.26
4/25/2006	1,400	\$66.27
5/4/2006	100	\$65.45
5/9/2006	100	\$71.00
5/10/2006	100	\$71.25
5/11/2006	400	\$71.24
5/12/2006	800	\$71.24
5/15/2006	400	\$70.82
5/17/2006	200	\$70.21
5/18/2006	300	\$70.47
5/19/2006	100	\$69.60
5/22/2006	200	\$69.43
5/23/2006	300	\$69.12
5/24/2006	300	\$66.58
5/24/2006	100	\$67.10
5/25/2006	500	\$67.90
5/26/2006	200	\$68.26
5/30/2006	200	\$66.86
5/31/2006	200	\$66.51
6/2/2006	200	\$66.91
6/6/2006	200	\$65.10

Page 44 of 51 Pages

SCHEDULE F

 TINICUM PARTNERS, L.P.

TRADE DATE -----	NO. OF SHARES PURCHASED -----	PRICE PER SHARE (\$) -----
4/10/2006	400	\$63.19
4/11/2006	100	\$62.11
4/17/2006	100	\$63.22
4/20/2006	300	\$66.25
4/21/2006	100	\$66.25
4/24/2006	400	\$66.26
4/25/2006	2,100	\$66.27
5/3/2006	100	\$65.01
5/4/2006	100	\$65.45
5/9/2006	100	\$71.00
5/10/2006	100	\$71.25
5/11/2006	300	\$71.24
5/12/2006	600	\$71.24
5/15/2006	200	\$70.82
5/17/2006	200	\$70.21
5/18/2006	300	\$70.47
5/19/2006	100	\$69.60
5/22/2006	200	\$69.43
5/23/2006	300	\$69.12
5/24/2006	300	\$66.58
5/24/2006	100	\$67.10
5/25/2006	500	\$67.90
5/26/2006	200	\$68.26
5/30/2006	200	\$66.86
5/31/2006	200	\$66.51
6/2/2006	200	\$66.91
6/6/2006	200	\$65.10

Page 45 of 51 Pages

SCHEDULE G

 FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

TRADE DATE	NO. OF SHARES PURCHASED	PRICE PER SHARE (\$)
4/10/2006	9,500	\$63.19
4/11/2006	1,200	\$62.11
4/12/2006	3	\$62.30
4/12/2006	497	\$62.30
4/13/2006	200	\$62.33
4/17/2006	1,300	\$63.22
4/18/2006	1,100	\$64.44
4/19/2006	200	\$65.09
4/20/2006	6,000	\$66.25
4/21/2006	2,900	\$66.25
4/24/2006	10,400	\$66.26
4/25/2006	61,300	\$66.27
5/3/2006	7,500	\$65.01
5/4/2006	9,100	\$65.45
5/9/2006	3,300	\$71.00
5/10/2006	2,800	\$71.25
5/11/2006	7,600	\$71.24
5/12/2006	15,300	\$71.24
5/15/2006	7,200	\$70.82
5/17/2006	6,000	\$70.21
5/18/2006	6,200	\$70.47
5/19/2006	3,000	\$69.60
5/22/2006	3,700	\$69.43
5/23/2006	4,800	\$69.12
5/24/2006	1,000	\$67.10
5/24/2006	5,100	\$66.58
5/25/2006	8,000	\$67.90
5/26/2006	4,300	\$68.26
5/30/2006	5,000	\$66.86
5/31/2006	5,000	\$66.51
6/2/2006	5,000	\$66.91
6/6/2006	4,300	\$65.10
6/8/2006	800	\$64.86

Page 46 of 51 Pages

SCHEDULE H

FARALLON CAPITAL MANAGEMENT, LLC

TRADE DATE	NO. OF SHARES PURCHASED	PRICE PER SHARE (\$)
4/10/2006	18,300	\$63.19
4/11/2006	2,400	\$62.11
4/12/2006	1,289	\$62.30
4/12/2006	11	\$62.30

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

4/13/2006	400	\$62.33
4/17/2006	2,907	\$63.22
4/18/2006	2,388	\$64.44
4/19/2006	569	\$65.09
4/20/2006	13,162	\$66.25
4/21/2006	5,595	\$66.25
4/24/2006	19,843	\$66.26
4/25/2006	117,136	\$66.27
5/3/2006	15,472	\$65.01
5/4/2006	19,328	\$65.45
5/9/2006	6,913	\$71.00
5/10/2006	5,634	\$71.25
5/11/2006	15,830	\$71.24
5/12/2006	31,300	\$71.24
5/15/2006	14,700	\$70.82
5/17/2006	12,900	\$70.21
5/18/2006	13,227	\$70.47
5/19/2006	6,373	\$69.60
5/22/2006	7,900	\$69.43
5/23/2006	10,700	\$69.12
5/24/2006	11,000	\$66.58
5/24/2006	2,100	\$67.10
5/25/2006	16,600	\$67.90
5/26/2006	11,600	\$68.26
5/30/2006	13,600	\$66.86
5/31/2006	14,000	\$66.51
6/2/2006	13,800	\$66.91
6/6/2006	11,700	\$65.10
6/8/2006	2,200	\$64.86
4/10/2006	2,000	\$63.19
4/11/2006	300	\$62.11
4/12/2006	99	\$62.30
4/12/2006	1	\$62.30

Page 47 of 51 Pages

4/17/2006	300	\$63.22
4/18/2006	200	\$64.44
4/20/2006	1,200	\$66.25
4/21/2006	600	\$66.25
4/24/2006	1,700	\$66.26
4/25/2006	10,600	\$66.27
5/3/2006	1,400	\$65.01
5/4/2006	1,700	\$65.45
5/9/2006	600	\$71.00
5/10/2006	600	\$71.25
5/11/2006	1,600	\$71.24
5/12/2006	3,200	\$71.24
5/15/2006	1,500	\$70.82
5/17/2006	1,400	\$70.21
5/18/2006	1,400	\$70.47
5/19/2006	700	\$69.60
5/22/2006	900	\$69.43
5/23/2006	1,200	\$69.12
5/24/2006	200	\$67.10

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

5/24/2006	1,300	\$66.58
5/25/2006	2,100	\$67.90
5/26/2006	800	\$68.26
5/30/2006	800	\$66.86
5/31/2006	800	\$66.51
6/2/2006	1,700	\$66.91
6/6/2006	1,400	\$65.10
6/8/2006	300	\$64.86

Page 48 of 51 Pages

EXHIBIT INDEX

EXHIBIT 1	Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
-----------	--

Page 49 of 51 Pages

EXHIBIT 1
to
SCHEDULE 13D

JOINT ACQUISITION STATEMENT
PURSUANT TO SECTION 240.13d-1(k)

Edgar Filing: BIO RAD LABORATORIES INC - Form SC 13D

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: June 9, 2006

/s/ Monica R. Landry

NOONDAY G.P. (U.S.), L.L.C.
By Monica R. Landry, Attorney-in-fact

/s/ Monica R. Landry

NOONDAY CAPITAL, L.L.C.,
On its own behalf
and as the General Partner of
NOONDAY ASSET MANAGEMENT, L.P.
By Monica R. Landry, Attorney-in-fact

/s/ Monica R. Landry

FARALLON PARTNERS, L.L.C.,
On its own behalf, as the General Partner of
FARALLON CAPITAL PARTNERS, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
TINICUM PARTNERS, L.P. and
FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.
and as the Managing Member of
NOONDAY CAPITAL PARTNERS, L.L.C.
By Monica R. Landry, Managing Member

Page 50 of 51 Pages

/s/ Monica R. Landry

FARALLON CAPITAL MANAGEMENT, L.L.C.
By Monica R. Landry, Managing Member

/s/ Monica R. Landry

Monica R. Landry, individually and as attorney-in-fact for
each of David I. Cohen, Chun R. Ding, William F. Duhamel,
Richard B. Fried, William F. Mellin, Stephen L. Millham,
Saurabh K. Mittal, Jason E. Moment, Rajiv A. Patel,
Derek C. Schrier, Thomas F. Steyer and Mark C. Wehrly

